ABL501, PD-L1 x LAG-3, a bispecific antibody promotes enhanced human T cell activation through targeting simultaneously two immune checkpoint inhibitors, LAG-3 and PD-L1.
- Authors
- Park, Eunyoung; Kim, Hyunejoo; Sung, Eunsil; Jung, Uijung; Hong, Youngeun; Lee, Hanbyul; Ko, Minkyung; Park, Yoon; Park, Chan Kwon; Kim, Seung Joon; Yoo, Jongman; Lee, Kyung Jin; Kim, Jihyo; Lee, Bo Eun; Won, Jonghwa; Jung, Jaeho
- Issue Date
- 2021-05
- Publisher
- AMER ASSOC CANCER RESEARCH
- Citation
- AACR Annual Meeting 2021
- ISSN
- 0008-5472
- URI
- https://pubs.kist.re.kr/handle/201004/77723
- Appears in Collections:
- KIST Conference Paper > 2021
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.